# Phase 02 clinical governance packet

Review ID: P02-R03
Status: PENDING
Date prepared: 2026-10-14

This review asks whether the Phase 02 safety architecture may remain in force as a development system. It is separate from production approval of the role matrix (`P02-R04`) and of emergency intended use (`P02-R05`).

## Submitted boundary
Clinical permissions in `authorize()` are labeled proposed. Unimplemented clinical actions are hard-denied. Emergency access reads one synthetic record and is disabled for production and staging. Organization administrators do not receive billing or audit read. No diagnosis, treatment recommendation, or production clinical record is created for the emergency scenario.

## Why a deferral is offered as a choice
The phase gate requires clinical, privacy, regulatory, and architecture reviewers to sign when needed before the phase is accepted. It also says engineering tests do not establish clinical readiness. A reviewer may accept the development boundary and explicitly defer production clinical policy. That deferral is allowed only if the reviewer records it. It is not assumed. If the reviewer decides a deferral is not enough, Phase 02 stays blocked on `P02-R03`.

## Decision requested
ACCEPT the development-only safety boundary, REQUEST CHANGES, or REJECT. Accepting this review does not approve the role matrix or production emergency use.
